RAP 0.00% 20.5¢ raptor resources limited

Brisbane, Australia, 23 August 2019 – ResApp Health Limited...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,091 Posts.
    lightbulb Created with Sketch. 2477
    Brisbane, Australia, 23 August 2019 – ResApp Health Limited (ASX:RAP), a leading digital healthcompany developing smartphone applications for the diagnosis and management of respiratorydisease, today announced that its first commercial product, ResAppDx-EU, has received CE Markcertification as a Class IIa medical device. ResAppDx-EU is the world’s first smartphone-baseddiagnostic test for acute paediatric respiratory disease. CE Mark certification indicates thatResAppDx-EU meets the essential requirements of all the applicable European regulations as amedical device and allows for the sale of ResAppDx-EU in the European Economic Area.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.